Carbonic anhydrase inhibition in the immediate therapy of acute mountain sickness

Journal of wilderness medicine Pub Date : 1994-02-01 DOI:10.1580/0953-9859-5.1.49

Alexander D. Wright FRCP, Michael H. Winterborn FRCP, Peter J. Forster MRCP, John P. Delamere FRCP, Ginette L. Harrison MRCOG, Arthur R. Bradwell FRCP, The Birmingham Medical Research Expeditionary Society, University of Birmingham

{"title":"Carbonic anhydrase inhibition in the immediate therapy of acute mountain sickness","authors":"Alexander D. Wright FRCP, Michael H. Winterborn FRCP, Peter J. Forster MRCP, John P. Delamere FRCP, Ginette L. Harrison MRCOG, Arthur R. Bradwell FRCP, The Birmingham Medical Research Expeditionary Society, University of Birmingham","doi":"10.1580/0953-9859-5.1.49","DOIUrl":null,"url":null,"abstract":"<div><p>The objective was to assess the effectiveness of acetazolamide and the relative speed of response to acetazolamide and methazolamide on blood gases and symptoms of acute mountain sickness (AMS). Thirty-seven subjects suffering from AMS were given 1–1.5 g acetazolamide or 400–500 mg methazolamide in randomized, double-blind trials during three expeditions to high altitude (3200–5486 m). Both drugs improved PaO<sub>2</sub> by 7.7–8.0 mmHg, with a more rapid response at 3 h following methazolamide. Symptom scores improved over 24 h following both drugs, but headaches were induced in 28% of subjects. It was concluded that treatment with acetazolamide and methazolamide improves arterial oxygenation and symptoms of AMS. The differences in time of response between the two drugs were not proven to be clinically important.</p></div>","PeriodicalId":81742,"journal":{"name":"Journal of wilderness medicine","volume":"5 1","pages":"Pages 49-55"},"PeriodicalIF":0.0000,"publicationDate":"1994-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1580/0953-9859-5.1.49","citationCount":"12","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of wilderness medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0953985994710949","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 12

Abstract

The objective was to assess the effectiveness of acetazolamide and the relative speed of response to acetazolamide and methazolamide on blood gases and symptoms of acute mountain sickness (AMS). Thirty-seven subjects suffering from AMS were given 1–1.5 g acetazolamide or 400–500 mg methazolamide in randomized, double-blind trials during three expeditions to high altitude (3200–5486 m). Both drugs improved PaO₂ by 7.7–8.0 mmHg, with a more rapid response at 3 h following methazolamide. Symptom scores improved over 24 h following both drugs, but headaches were induced in 28% of subjects. It was concluded that treatment with acetazolamide and methazolamide improves arterial oxygenation and symptoms of AMS. The differences in time of response between the two drugs were not proven to be clinically important.

查看原文本刊更多论文

碳酸酐酶抑制在急性高山病即时治疗中的应用

目的是评估乙酰唑胺的有效性以及乙酰唑胺和甲基唑胺对血气和急性高原反应(AMS)症状的相对反应速度。37例AMS患者在3次高海拔(3200 ~ 5486 m)的随机双盲试验中，分别给予1 ~ 1.5 g乙酰唑胺或400 ~ 500 mg甲唑胺，两种药物均能改善PaO2水平，改善幅度为77.8 ~ 8.0 mmHg，且甲唑胺治疗后3 h的反应速度更快。两种药物服用后24小时症状评分均有所改善，但28%的受试者出现头痛症状。结论乙酰唑胺和甲唑胺治疗可改善AMS的动脉氧合和症状。两种药物在反应时间上的差异在临床上并不重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of wilderness medicine

自引率

0.00%

发文量